In order to further improve the efficiency and efficacy of the existing PSMA radioligands for PCa diagnosis and radionuclide therapy several structural modifications have been suggested for reducing their uptake in off-target tissues or utilizing multitargeting (i.e., albumin, GRPr and integrin αvβ3). This evidence concerns the gene FOLH1 and posterior cortical atrophy.